07:22 AM EDT, 08/04/2025 (MT Newswires) -- TG Therapeutics ( TGTX ) reported Q2 net income Monday of $0.17 per diluted share, up from $0.04 a year earlier.

Analysts polled by FactSet expected $0.21.

Revenue for the quarter ended June 30 was $141.1 million, compared with $73.5 million a year earlier.

Analysts surveyed by FactSet expected $138 million.

For 2025, the company now expects global revenue of $585 million, compared with its prior guidance of $575 million.